EAM
GILD icon

Exome Asset Management’s Gilead Sciences GILD Stock Holding History

Exome Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,700
Closed -$2.74M – 67
2024
Q4 		$2.74M Sell
29,700
-20,300
-41% -$1.83M 2.06% 21
2024
Q3 		$4.19M Buy
+50,000
New +$3.82M 2.83% 8

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Exome Asset Management's GILD Position: Q1 2025 in Review

Exome Asset Management sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 29,700 shares — an estimated $2.74M sold.

Exome Asset Management first reported a position in GILD in Q3 2024 and held it in 2 quarters. The position peaked at $4.19M in Q3 2024. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

  • Exome Asset Management reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 29,700 Gilead Sciences shares in Q1 2025, an estimated $2.74M.
  • Exome Asset Management first reported a position in Gilead Sciences in Q3 2024 and held it in 2 quarters.
  • Exome Asset Management's Gilead Sciences position peaked at $4.19M in Q3 2024.
  • 2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.